{
  "model": "gpt-5.2",
  "taskId": "tumor-vaccine-ici",
  "runIndex": 1,
  "result": {
    "text": "- [x] `output/study_overview.json` written (matches `schemas/study_overview.schema.json`)\n- [x] `output/quantitative_findings.json` written (matches `schemas/quantitative_findings.schema.json`)\n- [x] `output/claim_audit.json` written (matches `schemas/claim_audit.schema.json`)\n- [x] `output/public_summary.json` written (matches `schemas/public_summary.schema.json`)",
    "thoughts": "",
    "steps": [
      {
        "step": 1,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_053109be666540f500698f618e14b48194a14d0219a0253cc2\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"TASK.md\\\",\\\"offset\\\":0,\\\"limit\\\":4000}\",\n  \"call_id\": \"call_xoOZdIgm8Lf6b6urFYqmIIBB\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "TASK.md",
              "offset": 0,
              "limit": 4000
            },
            "output": "L1: # Agent Task\nL2: \nL3: Task id: tumor-vaccine-ici\nL4: Task title: mRNA tumor sensitization for checkpoint blockade\nL5: Reference paper: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\nL6: Reference URL: https://www.nature.com/articles/s41586-025-09006-8\nL7: \nL8: ## Objective\nL9: Read the report and produce all required JSON outputs that satisfy their schemas.\nL10: \nL11: ## Inputs On Disk\nL12: - Report: `input/report.md`\nL13: - Schemas: in `schemas/`\nL14: \nL15: ## Required Outputs\nL16: - `output/study_overview.json` (schema: `schemas/study_overview.schema.json`)\nL17: - `output/quantitative_findings.json` (schema: `schemas/quantitative_findings.schema.json`)\nL18: - `output/claim_audit.json` (schema: `schemas/claim_audit.schema.json`)\nL19: - `output/public_summary.json` (schema: `schemas/public_summary.schema.json`)\nL20: \nL21: ## Constraints\nL22: - Do not invent source facts; derive calculations only from values in the report.\nL23: - Use line refs as `L<number>` where required.\nL24: - Where quotes are required, copy exact report snippets.\nL25: - For calculation outputs, line_refs must include every report line used for equations, constants, and numeric substitutions.\nL26: - Use relative paths only.\nL27: - Never use absolute paths.\nL28: - Never use `..` in paths.\nL29: - Write valid JSON only.\nL30: \nL31: ## Completion\nL32: Respond with a checklist of written output files.\nL33: After the checklist, stop. Do not call more tools.",
            "callId": "call_xoOZdIgm8Lf6b6urFYqmIIBB"
          }
        ],
        "usage": {
          "promptTokens": 561,
          "cachedTokens": 0,
          "responseTokens": 31,
          "thinkingTokens": 45,
          "totalTokens": 637
        },
        "costUsd": 0.00204575
      },
      {
        "step": 2,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_053109be666540f500698f619142808194b73de27260fcb022\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"dir_path\\\":\\\"schemas\\\",\\\"ignore\\\":null,\\\"file_filtering_options\\\":{\\\"respect_git_ignore\\\":null,\\\"respect_gemini_ignore\\\":null}}\",\n  \"call_id\": \"call_so75P1BsU8KIRL6a0kChVyZ1\",\n  \"name\": \"list_directory\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "list_directory",
            "input": {
              "dir_path": "schemas",
              "ignore": null,
              "file_filtering_options": {
                "respect_git_ignore": null,
                "respect_gemini_ignore": null
              }
            },
            "output": "claim_audit.schema.json\npublic_summary.schema.json\nquantitative_findings.schema.json\nstudy_overview.schema.json",
            "callId": "call_so75P1BsU8KIRL6a0kChVyZ1"
          }
        ],
        "usage": {
          "promptTokens": 1059,
          "cachedTokens": 0,
          "responseTokens": 44,
          "thinkingTokens": 31,
          "totalTokens": 1134
        },
        "costUsd": 0.00290325
      },
      {
        "step": 3,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_053109be666540f500698f61948d8c81949f3ab773afae51bc\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"input/report.md\\\",\\\"offset\\\":0,\\\"limit\\\":4000}\",\n  \"call_id\": \"call_pq5cqedCmELcLMUUjbVntztO\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_053109be666540f500698f61948d9c81948226bc144d5bb5e1\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"schemas/study_overview.schema.json\\\",\\\"offset\\\":0,\\\"limit\\\":4000}\",\n  \"call_id\": \"call_9rtfrignwU57EuzMy0bOnv1T\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_053109be666540f500698f61948da481948b89f908274c44e4\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"schemas/quantitative_findings.schema.json\\\",\\\"offset\\\":0,\\\"limit\\\":4000}\",\n  \"call_id\": \"call_H42t9jQ2GuHPYKsKVuQw72Yx\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_053109be666540f500698f61948dac8194976cf5f2f2675046\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"schemas/claim_audit.schema.json\\\",\\\"offset\\\":0,\\\"limit\\\":4000}\",\n  \"call_id\": \"call_5ClB2conTaiYLsGL6rZ4qQLG\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_053109be666540f500698f61948db081949de2e0d5947bfeda\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"schemas/public_summary.schema.json\\\",\\\"offset\\\":0,\\\"limit\\\":4000}\",\n  \"call_id\": \"call_W3YNmnsig4OdsWDL2b14Ve8U\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "input/report.md",
              "offset": 0,
              "limit": 4000
            },
            "output": "L1: # Structured Paper Report: Tumor Sensitization by mRNA Vaccination\nL2: \nL3: ## Citation\nL4: - Title: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\nL5: - Journal: Nature\nL6: - Year: 2025\nL7: - DOI: 10.1038/s41586-025-09006-8\nL8: - Source URL: https://www.nature.com/articles/s41586-025-09006-8\nL9: \nL10: ## One-Paragraph Context\nL11: Immune checkpoint inhibitors (ICIs) can produce durable responses in some cancers, but many tumors remain non-responsive due to weak antigen presentation or poor immune priming. The paper investigates whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy.\nL12: \nL13: ## Study Design Snapshot\nL14: - Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\nL15: - Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\nL16: - Mechanistic probes: immunopeptidomics, transcriptomics, and perturbation controls (including IFNAR1 blockade and non-mRNA particle controls).\nL17: \nL18: ## Cohorts and Scenarios\nL19: 1. Mouse efficacy cohort (combination therapy): 78 tumor-bearing mice pooled across repeat experiments.\nL20: 2. Mouse control cohort (vaccine only, ICI only, and vehicle): 84 tumor-bearing mice pooled across matched controls.\nL21: 3. Human retrospective metastatic cohort: 130 patients total.\nL22: 4. Human vaccinated subgroup: 43 patients.\nL23: 5. Human unvaccinated subgroup: 87 patients.\nL24: \nL25: ## Quantitative Findings\nL26: | Metric | Vaccine/Combination Arm | Comparator | Interpretation |\nL27: |---|---:|---:|---|\nL28: | Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |\nL29: | Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |\nL30: | Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\nL31: | Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |\nL32: | PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable |\nL33: | Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy |\nL34: \nL35: ## Controls and Null/Conditional Results\nL36: - Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\nL37: - ICI-only treatment had limited activity in low-immunogenic baseline settings.\nL38: - Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\nL39: - Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\nL40: \nL41: ## Mechanistic Chain Proposed by Authors\nL42: 1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\nL43: 2. Interferon-associated antigen processing and presentation pathways increase.\nL44: 3. A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\nL45: 4. PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\nL46: 5. Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\nL47: \nL48: ## Caveats and Threats to Validity\nL49: - The human analysis is retrospective and non-randomized; residual confounding is likely.\nL50: - Vaccination timing relative to ICI initiation varied across patients.\nL51: - Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\nL52: - Mouse model effects may not map one-to-one to all human tumors.\nL53: - Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\nL54: \nL55: ## Practical Takeaway\nL56: The study supports a biologically coherent hypothesis that intratumoral mRNA vaccination can prime tumors for stronger ICI responses, but prospective randomized studies are required before clinical protocol changes are justified.",
            "callId": "call_pq5cqedCmELcLMUUjbVntztO"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/study_overview.schema.json",
              "offset": 0,
              "limit": 4000
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-study_overview\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"paper\": {\nL7:       \"type\": \"object\",\nL8:       \"properties\": {\nL9:         \"title\": {\nL10:           \"type\": \"string\",\nL11:           \"minLength\": 10\nL12:         },\nL13:         \"doi\": {\nL14:           \"type\": \"string\",\nL15:           \"pattern\": \"^10\\\\.\"\nL16:         },\nL17:         \"publication_year\": {\nL18:           \"type\": \"integer\",\nL19:           \"minimum\": 1900,\nL20:           \"maximum\": 2100\nL21:         },\nL22:         \"domain\": {\nL23:           \"type\": \"string\",\nL24:           \"enum\": [\nL25:             \"oncology-immunology\",\nL26:             \"exoplanet-atmospheres\",\nL27:             \"climate-science\",\nL28:             \"neuroscience\",\nL29:             \"other\"\nL30:           ]\nL31:         },\nL32:         \"study_type\": {\nL33:           \"type\": \"string\",\nL34:           \"enum\": [\nL35:             \"preclinical+retrospective\",\nL36:             \"observational-astronomy\",\nL37:             \"randomized-trial\",\nL38:             \"simulation\",\nL39:             \"mixed\"\nL40:           ]\nL41:         }\nL42:       },\nL43:       \"required\": [\nL44:         \"title\",\nL45:         \"doi\",\nL46:         \"publication_year\",\nL47:         \"domain\",\nL48:         \"study_type\"\nL49:       ],\nL50:       \"additionalProperties\": false\nL51:     },\nL52:     \"core_question\": {\nL53:       \"type\": \"string\",\nL54:       \"minLength\": 20\nL55:     },\nL56:     \"datasets_or_cohorts\": {\nL57:       \"type\": \"array\",\nL58:       \"items\": {\nL59:         \"type\": \"object\",\nL60:         \"properties\": {\nL61:           \"id\": {\nL62:             \"type\": \"string\",\nL63:             \"pattern\": \"^[a-z0-9-]+$\"\nL64:           },\nL65:           \"label\": {\nL66:             \"type\": \"string\",\nL67:             \"minLength\": 3\nL68:           },\nL69:           \"sample_size_or_observations\": {\nL70:             \"type\": \"string\",\nL71:             \"minLength\": 1\nL72:           },\nL73:           \"description\": {\nL74:             \"type\": \"string\",\nL75:             \"minLength\": 20\nL76:           }\nL77:         },\nL78:         \"required\": [\nL79:           \"id\",\nL80:           \"label\",\nL81:           \"sample_size_or_observations\",\nL82:           \"description\"\nL83:         ],\nL84:         \"additionalProperties\": false\nL85:       },\nL86:       \"minItems\": 2,\nL87:       \"maxItems\": 8\nL88:     },\nL89:     \"major_limitations\": {\nL90:       \"type\": \"array\",\nL91:       \"items\": {\nL92:         \"type\": \"string\",\nL93:         \"minLength\": 12\nL94:       },\nL95:       \"minItems\": 3,\nL96:       \"maxItems\": 8\nL97:     }\nL98:   },\nL99:   \"required\": [\nL100:     \"paper\",\nL101:     \"core_question\",\nL102:     \"datasets_or_cohorts\",\nL103:     \"major_limitations\"\nL104:   ],\nL105:   \"additionalProperties\": false\nL106: }",
            "callId": "call_9rtfrignwU57EuzMy0bOnv1T"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/quantitative_findings.schema.json",
              "offset": 0,
              "limit": 4000
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-quantitative_findings\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"findings\": {\nL7:       \"type\": \"array\",\nL8:       \"items\": {\nL9:         \"type\": \"object\",\nL10:         \"properties\": {\nL11:           \"id\": {\nL12:             \"type\": \"string\",\nL13:             \"pattern\": \"^Q[0-9]{2}$\"\nL14:           },\nL15:           \"metric\": {\nL16:             \"type\": \"string\",\nL17:             \"minLength\": 6\nL18:           },\nL19:           \"value\": {\nL20:             \"type\": \"string\",\nL21:             \"minLength\": 1\nL22:           },\nL23:           \"comparator_or_baseline\": {\nL24:             \"type\": \"string\",\nL25:             \"minLength\": 1\nL26:           },\nL27:           \"interpretation\": {\nL28:             \"type\": \"string\",\nL29:             \"minLength\": 12\nL30:           },\nL31:           \"evidence_line_refs\": {\nL32:             \"type\": \"array\",\nL33:             \"items\": {\nL34:               \"type\": \"string\",\nL35:               \"pattern\": \"^L[1-9]\\\\d*$\"\nL36:             },\nL37:             \"minItems\": 1,\nL38:             \"maxItems\": 3\nL39:           }\nL40:         },\nL41:         \"required\": [\nL42:           \"id\",\nL43:           \"metric\",\nL44:           \"value\",\nL45:           \"comparator_or_baseline\",\nL46:           \"interpretation\",\nL47:           \"evidence_line_refs\"\nL48:         ],\nL49:         \"additionalProperties\": false\nL50:       },\nL51:       \"minItems\": 5,\nL52:       \"maxItems\": 14\nL53:     },\nL54:     \"controls_or_null_results\": {\nL55:       \"type\": \"array\",\nL56:       \"items\": {\nL57:         \"type\": \"object\",\nL58:         \"properties\": {\nL59:           \"statement\": {\nL60:             \"type\": \"string\",\nL61:             \"minLength\": 10\nL62:           },\nL63:           \"evidence_line_ref\": {\nL64:             \"$ref\": \"#/definitions/schemas-quantitative_findings/properties/findings/items/properties/evidence_line_refs/items\"\nL65:           }\nL66:         },\nL67:         \"required\": [\nL68:           \"statement\",\nL69:           \"evidence_line_ref\"\nL70:         ],\nL71:         \"additionalProperties\": false\nL72:       },\nL73:       \"minItems\": 2,\nL74:       \"maxItems\": 10\nL75:     }\nL76:   },\nL77:   \"required\": [\nL78:     \"findings\",\nL79:     \"controls_or_null_results\"\nL80:   ],\nL81:   \"additionalProperties\": false\nL82: }",
            "callId": "call_H42t9jQ2GuHPYKsKVuQw72Yx"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/claim_audit.schema.json",
              "offset": 0,
              "limit": 4000
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-claim_audit\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"claims\": {\nL7:       \"type\": \"array\",\nL8:       \"items\": {\nL9:         \"type\": \"object\",\nL10:         \"properties\": {\nL11:           \"claim_id\": {\nL12:             \"type\": \"string\",\nL13:             \"pattern\": \"^C[0-9]{2}$\"\nL14:           },\nL15:           \"claim\": {\nL16:             \"type\": \"string\",\nL17:             \"minLength\": 20\nL18:           },\nL19:           \"strength\": {\nL20:             \"type\": \"string\",\nL21:             \"enum\": [\nL22:               \"strong\",\nL23:               \"moderate\",\nL24:               \"tentative\"\nL25:             ]\nL26:           },\nL27:           \"evidence\": {\nL28:             \"type\": \"array\",\nL29:             \"items\": {\nL30:               \"type\": \"object\",\nL31:               \"properties\": {\nL32:                 \"quote\": {\nL33:                   \"type\": \"string\",\nL34:                   \"minLength\": 10\nL35:                 },\nL36:                 \"line_ref\": {\nL37:                   \"type\": \"string\",\nL38:                   \"pattern\": \"^L[1-9]\\\\d*$\"\nL39:                 }\nL40:               },\nL41:               \"required\": [\nL42:                 \"quote\",\nL43:                 \"line_ref\"\nL44:               ],\nL45:               \"additionalProperties\": false\nL46:             },\nL47:             \"minItems\": 2,\nL48:             \"maxItems\": 3\nL49:           },\nL50:           \"caveat\": {\nL51:             \"type\": \"string\",\nL52:             \"minLength\": 20\nL53:           }\nL54:         },\nL55:         \"required\": [\nL56:           \"claim_id\",\nL57:           \"claim\",\nL58:           \"strength\",\nL59:           \"evidence\",\nL60:           \"caveat\"\nL61:         ],\nL62:         \"additionalProperties\": false\nL63:       },\nL64:       \"minItems\": 4,\nL65:       \"maxItems\": 10\nL66:     }\nL67:   },\nL68:   \"required\": [\nL69:     \"claims\"\nL70:   ],\nL71:   \"additionalProperties\": false\nL72: }",
            "callId": "call_5ClB2conTaiYLsGL6rZ4qQLG"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/public_summary.schema.json",
              "offset": 0,
              "limit": 4000
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-public_summary\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"headline\": {\nL7:       \"type\": \"string\",\nL8:       \"minLength\": 20,\nL9:       \"maxLength\": 120\nL10:     },\nL11:     \"plain_language_summary\": {\nL12:       \"type\": \"string\",\nL13:       \"minLength\": 180,\nL14:       \"maxLength\": 1200\nL15:     },\nL16:     \"what_is_new\": {\nL17:       \"type\": \"array\",\nL18:       \"items\": {\nL19:         \"type\": \"string\",\nL20:         \"minLength\": 20\nL21:       },\nL22:       \"minItems\": 3,\nL23:       \"maxItems\": 3\nL24:     },\nL25:     \"why_caution_is_needed\": {\nL26:       \"type\": \"array\",\nL27:       \"items\": {\nL28:         \"type\": \"string\",\nL29:         \"minLength\": 20\nL30:       },\nL31:       \"minItems\": 3,\nL32:       \"maxItems\": 5\nL33:     },\nL34:     \"glossary\": {\nL35:       \"type\": \"array\",\nL36:       \"items\": {\nL37:         \"type\": \"object\",\nL38:         \"properties\": {\nL39:           \"term\": {\nL40:             \"type\": \"string\",\nL41:             \"minLength\": 2\nL42:           },\nL43:           \"definition\": {\nL44:             \"type\": \"string\",\nL45:             \"minLength\": 20,\nL46:             \"maxLength\": 220\nL47:           }\nL48:         },\nL49:         \"required\": [\nL50:           \"term\",\nL51:           \"definition\"\nL52:         ],\nL53:         \"additionalProperties\": false\nL54:       },\nL55:       \"minItems\": 4,\nL56:       \"maxItems\": 8\nL57:     },\nL58:     \"open_questions\": {\nL59:       \"type\": \"array\",\nL60:       \"items\": {\nL61:         \"type\": \"string\",\nL62:         \"minLength\": 20\nL63:       },\nL64:       \"minItems\": 3,\nL65:       \"maxItems\": 6\nL66:     }\nL67:   },\nL68:   \"required\": [\nL69:     \"headline\",\nL70:     \"plain_language_summary\",\nL71:     \"what_is_new\",\nL72:     \"why_caution_is_needed\",\nL73:     \"glossary\",\nL74:     \"open_questions\"\nL75:   ],\nL76:   \"additionalProperties\": false\nL77: }",
            "callId": "call_W3YNmnsig4OdsWDL2b14Ve8U"
          }
        ],
        "usage": {
          "promptTokens": 1168,
          "cachedTokens": 0,
          "responseTokens": 165,
          "thinkingTokens": 0,
          "totalTokens": 1333
        },
        "costUsd": 0.004354
      },
      {
        "step": 4,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_053109be666540f500698f61aa8c0c8194b7b42f5d09f7f447\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"dir_path\\\":\\\".\\\",\\\"ignore\\\":null,\\\"file_filtering_options\\\":{\\\"respect_git_ignore\\\":null,\\\"respect_gemini_ignore\\\":null}}\",\n  \"call_id\": \"call_uUYhhwuv9eqc3KMQ3bqSoxUx\",\n  \"name\": \"list_directory\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "list_directory",
            "input": {
              "dir_path": ".",
              "ignore": null,
              "file_filtering_options": {
                "respect_git_ignore": null,
                "respect_gemini_ignore": null
              }
            },
            "output": "input/\noutput/\nschemas/\nTASK.md",
            "callId": "call_uUYhhwuv9eqc3KMQ3bqSoxUx"
          }
        ],
        "usage": {
          "promptTokens": 5363,
          "cachedTokens": 1152,
          "responseTokens": 44,
          "thinkingTokens": 1016,
          "totalTokens": 6423
        },
        "costUsd": 0.02241085
      },
      {
        "step": 5,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_053109be666540f500698f61e01c4c8194b53d2d6787355854\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"output/study_overview.json\\\",\\\"content\\\":\\\"{\\\\n  \\\\\\\"paper\\\\\\\": {\\\\n    \\\\\\\"title\\\\\\\": \\\\\\\"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\\\\\\\",\\\\n    \\\\\\\"doi\\\\\\\": \\\\\\\"10.1038/s41586-025-09006-8\\\\\\\",\\\\n    \\\\\\\"publication_year\\\\\\\": 2025,\\\\n    \\\\\\\"domain\\\\\\\": \\\\\\\"oncology-immunology\\\\\\\",\\\\n    \\\\\\\"study_type\\\\\\\": \\\\\\\"preclinical+retrospective\\\\\\\"\\\\n  },\\\\n  \\\\\\\"core_question\\\\\\\": \\\\\\\"Whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy.\\\\\\\",\\\\n  \\\\\\\"datasets_or_cohorts\\\\\\\": [\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"mouse-efficacy\\\\\\\",\\\\n      \\\\\\\"label\\\\\\\": \\\\\\\"Mouse efficacy cohort (combination therapy)\\\\\\\",\\\\n      \\\\\\\"sample_size_or_observations\\\\\\\": \\\\\\\"78 tumor-bearing mice\\\\\\\",\\\\n      \\\\\\\"description\\\\\\\": \\\\\\\"Pooled across repeat experiments in multiple murine tumor models testing intratumoral mRNA vaccine with anti-PD-L1 combinations.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"mouse-controls\\\\\\\",\\\\n      \\\\\\\"label\\\\\\\": \\\\\\\"Mouse control cohort\\\\\\\",\\\\n      \\\\\\\"sample_size_or_observations\\\\\\\": \\\\\\\"84 tumor-bearing mice\\\\\\\",\\\\n      \\\\\\\"description\\\\\\\": \\\\\\\"Matched controls pooled across experiments, including vaccine only, ICI only, and vehicle conditions in murine tumor models.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"human-retrospective\\\\\\\",\\\\n      \\\\\\\"label\\\\\\\": \\\\\\\"Human retrospective metastatic cohort\\\\\\\",\\\\n      \\\\\\\"sample_size_or_observations\\\\\\\": \\\\\\\"130 patients\\\\\\\",\\\\n      \\\\\\\"description\\\\\\\": \\\\\\\"Retrospective metastatic patient cohort receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"human-vaccinated\\\\\\\",\\\\n      \\\\\\\"label\\\\\\\": \\\\\\\"Human vaccinated subgroup\\\\\\\",\\\\n      \\\\\\\"sample_size_or_observations\\\\\\\": \\\\\\\"43 patients\\\\\\\",\\\\n      \\\\\\\"description\\\\\\\": \\\\\\\"Subset of the retrospective metastatic cohort with prior SARS-CoV-2 mRNA vaccination before or during ICI treatment.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"human-unvaccinated\\\\\\\",\\\\n      \\\\\\\"label\\\\\\\": \\\\\\\"Human unvaccinated subgroup\\\\\\\",\\\\n      \\\\\\\"sample_size_or_observations\\\\\\\": \\\\\\\"87 patients\\\\\\\",\\\\n      \\\\\\\"description\\\\\\\": \\\\\\\"Subset of the retrospective metastatic cohort without prior SARS-CoV-2 mRNA vaccination, used as the comparator group for outcomes under ICI.\\\\\\\"\\\\n    }\\\\n  ],\\\\n  \\\\\\\"major_limitations\\\\\\\": [\\\\n    \\\\\\\"The human analysis is retrospective and non-randomized; residual confounding is likely.\\\\\\\",\\\\n    \\\\\\\"Vaccination timing relative to ICI initiation varied across patients.\\\\\\\",\\\\n    \\\\\\\"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\\\\\\\",\\\\n    \\\\\\\"Mouse model effects may not map one-to-one to all human tumors.\\\\\\\",\\\\n    \\\\\\\"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\\\\\\\"\\\\n  ]\\\\n}\\\"}\",\n  \"call_id\": \"call_WaxUvjzo6UroFickrbMCN9Hs\",\n  \"name\": \"write_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_053109be666540f500698f61e01c5c8194978696d6fad80599\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"output/quantitative_findings.json\\\",\\\"content\\\":\\\"{\\\\n  \\\\\\\"findings\\\\\\\": [\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"Q01\\\\\\\",\\\\n      \\\\\\\"metric\\\\\\\": \\\\\\\"Fraction of tumor proteins represented in immunopeptidome\\\\\\\",\\\\n      \\\\\\\"value\\\\\\\": \\\\\\\"62.3%\\\\\\\",\\\\n      \\\\\\\"comparator_or_baseline\\\\\\\": \\\\\\\"37.3%\\\\\\\",\\\\n      \\\\\\\"interpretation\\\\\\\": \\\\\\\"Intratumoral mRNA vaccination was associated with broader antigen display in the tumor immunopeptidome.\\\\\\\",\\\\n      \\\\\\\"evidence_line_refs\\\\\\\": [\\\\n        \\\\\\\"L28\\\\\\\"\\\\n      ]\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"Q02\\\\\\\",\\\\n      \\\\\\\"metric\\\\\\\": \\\\\\\"Fraction of proteins represented in MHC-I peptidome\\\\\\\",\\\\n      \\\\\\\"value\\\\\\\": \\\\\\\"40.6%\\\\\\\",\\\\n      \\\\\\\"comparator_or_baseline\\\\\\\": \\\\\\\"20.6%\\\\\\\",\\\\n      \\\\\\\"interpretation\\\\\\\": \\\\\\\"The MHC-I-presented peptide landscape expanded substantially after intratumoral mRNA vaccination.\\\\\\\",\\\\n      \\\\\\\"evidence_line_refs\\\\\\\": [\\\\n        \\\\\\\"L29\\\\\\\"\\\\n      ]\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"Q03\\\\\\\",\\\\n      \\\\\\\"metric\\\\\\\": \\\\\\\"Retrospective human survival comparison p-value\\\\\\\",\\\\n      \\\\\\\"value\\\\\\\": \\\\\\\"p=0.01\\\\\\\",\\\\n      \\\\\\\"comparator_or_baseline\\\\\\\": \\\\\\\"N/A\\\\\\\",\\\\n      \\\\\\\"interpretation\\\\\\\": \\\\\\\"In the retrospective metastatic cohort, prior SARS-CoV-2 mRNA vaccination status was associated with improved survival under ICI treatment.\\\\\\\",\\\\n      \\\\\\\"evidence_line_refs\\\\\\\": [\\\\n        \\\\\\\"L30\\\\\\\"\\\\n      ]\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"Q04\\\\\\\",\\\\n      \\\\\\\"metric\\\\\\\": \\\\\\\"Type I interferon response score (normalized units)\\\\\\\",\\\\n      \\\\\\\"value\\\\\\\": \\\\\\\"3.1\\\\\\\",\\\\n      \\\\\\\"comparator_or_baseline\\\\\\\": \\\\\\\"1.0\\\\\\\",\\\\n      \\\\\\\"interpretation\\\\\\\": \\\\\\\"Tumors showed a marked induction of a type I interferon response after mRNA vaccination.\\\\\\\",\\\\n      \\\\\\\"evidence_line_refs\\\\\\\": [\\\\n        \\\\\\\"L31\\\\\\\"\\\\n      ]\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"Q05\\\\\\\",\\\\n      \\\\\\\"metric\\\\\\\": \\\\\\\"PD-L1 expression fold-change in tumor tissue\\\\\\\",\\\\n      \\\\\\\"value\\\\\\\": \\\\\\\"2.4x\\\\\\\",\\\\n      \\\\\\\"comparator_or_baseline\\\\\\\": \\\\\\\"1.0x\\\\\\\",\\\\n      \\\\\\\"interpretation\\\\\\\": \\\\\\\"PD-L1 expression increased after vaccination, consistent with the checkpoint axis becoming more targetable.\\\\\\\",\\\\n      \\\\\\\"evidence_line_refs\\\\\\\": [\\\\n        \\\\\\\"L32\\\\\\\"\\\\n      ]\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"Q06\\\\\\\",\\\\n      \\\\\\\"metric\\\\\\\": \\\\\\\"Intratumoral CD8+ T-cell density fold-change\\\\\\\",\\\\n      \\\\\\\"value\\\\\\\": \\\\\\\"1.8x\\\\\\\",\\\\n      \\\\\\\"comparator_or_baseline\\\\\\\": \\\\\\\"1.0x\\\\\\\",\\\\n      \\\\\\\"interpretation\\\\\\\": \\\\\\\"Combination therapy was associated with increased intratumoral CD8+ T-cell density, consistent with increased immune infiltration.\\\\\\\",\\\\n      \\\\\\\"evidence_line_refs\\\\\\\": [\\\\n        \\\\\\\"L33\\\\\\\"\\\\n      ]\\\\n    }\\\\n  ],\\\\n  \\\\\\\"controls_or_null_results\\\\\\\": [\\\\n    {\\\\n      \\\\\\\"statement\\\\\\\": \\\\\\\"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\\\\\\\",\\\\n      \\\\\\\"evidence_line_ref\\\\\\\": \\\\\\\"L36\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"statement\\\\\\\": \\\\\\\"ICI-only treatment had limited activity in low-immunogenic baseline settings.\\\\\\\",\\\\n      \\\\\\\"evidence_line_ref\\\\\\\": \\\\\\\"L37\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"statement\\\\\\\": \\\\\\\"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\\\\\\\",\\\\n      \\\\\\\"evidence_line_ref\\\\\\\": \\\\\\\"L38\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"statement\\\\\\\": \\\\\\\"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\\\\\\\",\\\\n      \\\\\\\"evidence_line_ref\\\\\\\": \\\\\\\"L39\\\\\\\"\\\\n    }\\\\n  ]\\\\n}\\\"}\",\n  \"call_id\": \"call_CMXennH7ZPYyCiRjbd9hKXj4\",\n  \"name\": \"write_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_053109be666540f500698f61e01c688194855db7e9d4c91def\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"output/claim_audit.json\\\",\\\"content\\\":\\\"{\\\\n  \\\\\\\"claims\\\\\\\": [\\\\n    {\\\\n      \\\\\\\"claim_id\\\\\\\": \\\\\\\"C01\\\\\\\",\\\\n      \\\\\\\"claim\\\\\\\": \\\\\\\"Intratumoral mRNA vaccination broadens tumor antigen display, increasing the represented proteins in both the immunopeptidome and the MHC-I peptidome.\\\\\\\",\\\\n      \\\\\\\"strength\\\\\\\": \\\\\\\"moderate\\\\\\\",\\\\n      \\\\\\\"evidence\\\\\\\": [\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"| Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L28\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"| Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L29\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L44\\\\\\\"\\\\n        }\\\\n      ],\\\\n      \\\\\\\"caveat\\\\\\\": \\\\\\\"These summary values do not specify tumor-model variability, and some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"claim_id\\\\\\\": \\\\\\\"C02\\\\\\\",\\\\n      \\\\\\\"claim\\\\\\\": \\\\\\\"Intratumoral mRNA vaccination induces a type I interferon response in tumors, and type I interferon signaling is required for the sensitization benefit.\\\\\\\",\\\\n      \\\\\\\"strength\\\\\\\": \\\\\\\"strong\\\\\\\",\\\\n      \\\\\\\"evidence\\\\\\\": [\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L42\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"| Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L31\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"- Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L39\\\\\\\"\\\\n        }\\\\n      ],\\\\n      \\\\\\\"caveat\\\\\\\": \\\\\\\"The report summarizes the mechanism at a high level; mouse model effects may not map one-to-one to all human tumors.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"claim_id\\\\\\\": \\\\\\\"C03\\\\\\\",\\\\n      \\\\\\\"claim\\\\\\\": \\\\\\\"mRNA vaccination increases PD-L1 pathway activity in tumor tissue, providing a rationale for combining intratumoral vaccination with anti-PD-L1 checkpoint blockade.\\\\\\\",\\\\n      \\\\\\\"strength\\\\\\\": \\\\\\\"moderate\\\\\\\",\\\\n      \\\\\\\"evidence\\\\\\\": [\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"| PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable |\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L32\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L45\\\\\\\"\\\\n        }\\\\n      ],\\\\n      \\\\\\\"caveat\\\\\\\": \\\\\\\"An increase in PD-L1 expression does not by itself guarantee clinical benefit, and translation from mouse tumor settings to diverse human tumors is uncertain.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"claim_id\\\\\\\": \\\\\\\"C04\\\\\\\",\\\\n      \\\\\\\"claim\\\\\\\": \\\\\\\"Combination treatment with intratumoral mRNA vaccination and anti-PD-L1 is associated with increased intratumoral CD8+ T-cell density and improved tumor control in mice.\\\\\\\",\\\\n      \\\\\\\"strength\\\\\\\": \\\\\\\"moderate\\\\\\\",\\\\n      \\\\\\\"evidence\\\\\\\": [\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"- Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L14\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"| Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy |\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L33\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L46\\\\\\\"\\\\n        }\\\\n      ],\\\\n      \\\\\\\"caveat\\\\\\\": \\\\\\\"The magnitude and consistency of these effects may vary by model system, and mouse model effects may not map one-to-one to all human tumors.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"claim_id\\\\\\\": \\\\\\\"C05\\\\\\\",\\\\n      \\\\\\\"claim\\\\\\\": \\\\\\\"In a retrospective metastatic patient cohort treated with immune checkpoint inhibitors, prior SARS-CoV-2 mRNA vaccination status was associated with improved survival.\\\\\\\",\\\\n      \\\\\\\"strength\\\\\\\": \\\\\\\"tentative\\\\\\\",\\\\n      \\\\\\\"evidence\\\\\\\": [\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"- Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L15\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"| Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L30\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"- The human analysis is retrospective and non-randomized; residual confounding is likely.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L49\\\\\\\"\\\\n        }\\\\n      ],\\\\n      \\\\\\\"caveat\\\\\\\": \\\\\\\"Because the human analysis is retrospective and non-randomized with variable vaccination timing and heterogeneous tumor types, the observed association cannot be interpreted as definitive causation.\\\\\\\"\\\\n    }\\\\n  ]\\\\n}\\\"}\",\n  \"call_id\": \"call_2AvPCg9lX7Ciaxj91H6qJcSQ\",\n  \"name\": \"write_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_053109be666540f500698f61e01c708194ab0377ac71421006\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"output/public_summary.json\\\",\\\"content\\\":\\\"{\\\\n  \\\\\\\"headline\\\\\\\": \\\\\\\"Intratumoral mRNA vaccination may prime tumors to respond better to anti-PD-L1 therapy\\\\\\\",\\\\n  \\\\\\\"plain_language_summary\\\\\\\": \\\\\\\"Immune checkpoint inhibitors (ICIs) can lead to long-lasting cancer responses, but many tumors do not respond well. This study tests the idea that delivering an mRNA vaccine directly into a tumor could create a strong local inflammatory signal (especially type I interferon), which in turn boosts how well tumors process and display antigens to the immune system. In mouse tumor models, the authors report that intratumoral mRNA vaccination broadens the MHC-I peptide repertoire and increases immune-related signals, including higher PD-L1 activity and increased CD8+ T-cell presence with combination treatment. The paper also includes a retrospective analysis of 130 metastatic patients treated with ICIs, where the vaccinated subgroup (43 patients) showed improved survival compared with the unvaccinated subgroup (87 patients), with a reported p-value of 0.01. Because the human analysis is retrospective and non-randomized, the findings support a plausible biological hypothesis but do not yet justify changes to clinical practice without prospective randomized trials.\\\\\\\",\\\\n  \\\\\\\"what_is_new\\\\\\\": [\\\\n    \\\\\\\"The work links intratumoral mRNA vaccination to an interferon-rich tumor state that can sensitize tumors to anti-PD-L1 therapy.\\\\\\\",\\\\n    \\\\\\\"It reports broader antigen presentation after vaccination, with higher fractions of proteins represented in the immunopeptidome and the MHC-I peptidome.\\\\\\\",\\\\n    \\\\\\\"It pairs preclinical mouse evidence with a retrospective human cohort comparison by SARS-CoV-2 mRNA vaccination status during ICI treatment.\\\\\\\"\\\\n  ],\\\\n  \\\\\\\"why_caution_is_needed\\\\\\\": [\\\\n    \\\\\\\"The human survival comparison is retrospective and non-randomized, so residual confounding is likely.\\\\\\\",\\\\n    \\\\\\\"Vaccination timing relative to ICI initiation varied, and tumor types and prior treatments were heterogeneous.\\\\\\\",\\\\n    \\\\\\\"Mouse model results may not translate directly to all human tumors, and some mechanistic signals were strongest in specific settings.\\\\\\\"\\\\n  ],\\\\n  \\\\\\\"glossary\\\\\\\": [\\\\n    {\\\\n      \\\\\\\"term\\\\\\\": \\\\\\\"Intratumoral\\\\\\\",\\\\n      \\\\\\\"definition\\\\\\\": \\\\\\\"A route of administration in which a treatment is delivered directly into the tumor rather than systemically.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"term\\\\\\\": \\\\\\\"mRNA vaccine\\\\\\\",\\\\n      \\\\\\\"definition\\\\\\\": \\\\\\\"A vaccine platform that uses messenger RNA to instruct cells to produce a protein that can trigger immune activation.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"term\\\\\\\": \\\\\\\"Type I interferon\\\\\\\",\\\\n      \\\\\\\"definition\\\\\\\": \\\\\\\"A family of immune signaling molecules involved in antiviral defense that can also promote inflammation and antigen presentation.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"term\\\\\\\": \\\\\\\"Immune checkpoint inhibitor (ICI)\\\\\\\",\\\\n      \\\\\\\"definition\\\\\\\": \\\\\\\"A cancer therapy that blocks inhibitory immune pathways, such as PD-1/PD-L1, to help T cells attack tumors.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"term\\\\\\\": \\\\\\\"MHC-I\\\\\\\",\\\\n      \\\\\\\"definition\\\\\\\": \\\\\\\"A molecule on cells that presents peptide fragments to CD8+ T cells, helping the immune system recognize abnormal cells.\\\\\\\"\\\\n    }\\\\n  ],\\\\n  \\\\\\\"open_questions\\\\\\\": [\\\\n    \\\\\\\"Would the sensitization effect hold up in prospective randomized clinical trials across different tumor types?\\\\\\\",\\\\n    \\\\\\\"How much do vaccination timing and dose relative to ICI initiation influence outcomes and immune readouts?\\\\\\\",\\\\n    \\\\\\\"Which patients or tumor features predict the strongest interferon induction and antigen-presentation changes after intratumoral mRNA vaccination?\\\\\\\"\\\\n  ]\\\\n}\\\"}\",\n  \"call_id\": \"call_0Iy18wGG9FN5zyLcL9Qinapo\",\n  \"name\": \"write_file\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/study_overview.json",
              "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy.\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy\",\n      \"label\": \"Mouse efficacy cohort (combination therapy)\",\n      \"sample_size_or_observations\": \"78 tumor-bearing mice\",\n      \"description\": \"Pooled across repeat experiments in multiple murine tumor models testing intratumoral mRNA vaccine with anti-PD-L1 combinations.\"\n    },\n    {\n      \"id\": \"mouse-controls\",\n      \"label\": \"Mouse control cohort\",\n      \"sample_size_or_observations\": \"84 tumor-bearing mice\",\n      \"description\": \"Matched controls pooled across experiments, including vaccine only, ICI only, and vehicle conditions in murine tumor models.\"\n    },\n    {\n      \"id\": \"human-retrospective\",\n      \"label\": \"Human retrospective metastatic cohort\",\n      \"sample_size_or_observations\": \"130 patients\",\n      \"description\": \"Retrospective metastatic patient cohort receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\"\n    },\n    {\n      \"id\": \"human-vaccinated\",\n      \"label\": \"Human vaccinated subgroup\",\n      \"sample_size_or_observations\": \"43 patients\",\n      \"description\": \"Subset of the retrospective metastatic cohort with prior SARS-CoV-2 mRNA vaccination before or during ICI treatment.\"\n    },\n    {\n      \"id\": \"human-unvaccinated\",\n      \"label\": \"Human unvaccinated subgroup\",\n      \"sample_size_or_observations\": \"87 patients\",\n      \"description\": \"Subset of the retrospective metastatic cohort without prior SARS-CoV-2 mRNA vaccination, used as the comparator group for outcomes under ICI.\"\n    }\n  ],\n  \"major_limitations\": [\n    \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n    \"Vaccination timing relative to ICI initiation varied across patients.\",\n    \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\n    \"Mouse model effects may not map one-to-one to all human tumors.\",\n    \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n  ]\n}"
            },
            "output": "Successfully wrote file: output/study_overview.json",
            "callId": "call_WaxUvjzo6UroFickrbMCN9Hs"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3%\",\n      \"interpretation\": \"Intratumoral mRNA vaccination was associated with broader antigen display in the tumor immunopeptidome.\",\n      \"evidence_line_refs\": [\n        \"L28\"\n      ]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6%\",\n      \"interpretation\": \"The MHC-I-presented peptide landscape expanded substantially after intratumoral mRNA vaccination.\",\n      \"evidence_line_refs\": [\n        \"L29\"\n      ]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"N/A\",\n      \"interpretation\": \"In the retrospective metastatic cohort, prior SARS-CoV-2 mRNA vaccination status was associated with improved survival under ICI treatment.\",\n      \"evidence_line_refs\": [\n        \"L30\"\n      ]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0\",\n      \"interpretation\": \"Tumors showed a marked induction of a type I interferon response after mRNA vaccination.\",\n      \"evidence_line_refs\": [\n        \"L31\"\n      ]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"PD-L1 expression increased after vaccination, consistent with the checkpoint axis becoming more targetable.\",\n      \"evidence_line_refs\": [\n        \"L32\"\n      ]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Combination therapy was associated with increased intratumoral CD8+ T-cell density, consistent with increased immune infiltration.\",\n      \"evidence_line_refs\": [\n        \"L33\"\n      ]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n      \"evidence_line_ref\": \"L38\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}"
            },
            "output": "Successfully wrote file: output/quantitative_findings.json",
            "callId": "call_CMXennH7ZPYyCiRjbd9hKXj4"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination broadens tumor antigen display, increasing the represented proteins in both the immunopeptidome and the MHC-I peptidome.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"| Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |\",\n          \"line_ref\": \"L28\"\n        },\n        {\n          \"quote\": \"| Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |\",\n          \"line_ref\": \"L29\"\n        },\n        {\n          \"quote\": \"A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\",\n          \"line_ref\": \"L44\"\n        }\n      ],\n      \"caveat\": \"These summary values do not specify tumor-model variability, and some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"Intratumoral mRNA vaccination induces a type I interferon response in tumors, and type I interferon signaling is required for the sensitization benefit.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        },\n        {\n          \"quote\": \"| Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |\",\n          \"line_ref\": \"L31\"\n        },\n        {\n          \"quote\": \"- Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n          \"line_ref\": \"L39\"\n        }\n      ],\n      \"caveat\": \"The report summarizes the mechanism at a high level; mouse model effects may not map one-to-one to all human tumors.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"mRNA vaccination increases PD-L1 pathway activity in tumor tissue, providing a rationale for combining intratumoral vaccination with anti-PD-L1 checkpoint blockade.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"| PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable |\",\n          \"line_ref\": \"L32\"\n        },\n        {\n          \"quote\": \"PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\",\n          \"line_ref\": \"L45\"\n        }\n      ],\n      \"caveat\": \"An increase in PD-L1 expression does not by itself guarantee clinical benefit, and translation from mouse tumor settings to diverse human tumors is uncertain.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"Combination treatment with intratumoral mRNA vaccination and anti-PD-L1 is associated with increased intratumoral CD8+ T-cell density and improved tumor control in mice.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"- Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\",\n          \"line_ref\": \"L14\"\n        },\n        {\n          \"quote\": \"| Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy |\",\n          \"line_ref\": \"L33\"\n        },\n        {\n          \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\n          \"line_ref\": \"L46\"\n        }\n      ],\n      \"caveat\": \"The magnitude and consistency of these effects may vary by model system, and mouse model effects may not map one-to-one to all human tumors.\"\n    },\n    {\n      \"claim_id\": \"C05\",\n      \"claim\": \"In a retrospective metastatic patient cohort treated with immune checkpoint inhibitors, prior SARS-CoV-2 mRNA vaccination status was associated with improved survival.\",\n      \"strength\": \"tentative\",\n      \"evidence\": [\n        {\n          \"quote\": \"- Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\",\n          \"line_ref\": \"L15\"\n        },\n        {\n          \"quote\": \"| Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\",\n          \"line_ref\": \"L30\"\n        },\n        {\n          \"quote\": \"- The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n          \"line_ref\": \"L49\"\n        }\n      ],\n      \"caveat\": \"Because the human analysis is retrospective and non-randomized with variable vaccination timing and heterogeneous tumor types, the observed association cannot be interpreted as definitive causation.\"\n    }\n  ]\n}"
            },
            "output": "Successfully wrote file: output/claim_audit.json",
            "callId": "call_2AvPCg9lX7Ciaxj91H6qJcSQ"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/public_summary.json",
              "content": "{\n  \"headline\": \"Intratumoral mRNA vaccination may prime tumors to respond better to anti-PD-L1 therapy\",\n  \"plain_language_summary\": \"Immune checkpoint inhibitors (ICIs) can lead to long-lasting cancer responses, but many tumors do not respond well. This study tests the idea that delivering an mRNA vaccine directly into a tumor could create a strong local inflammatory signal (especially type I interferon), which in turn boosts how well tumors process and display antigens to the immune system. In mouse tumor models, the authors report that intratumoral mRNA vaccination broadens the MHC-I peptide repertoire and increases immune-related signals, including higher PD-L1 activity and increased CD8+ T-cell presence with combination treatment. The paper also includes a retrospective analysis of 130 metastatic patients treated with ICIs, where the vaccinated subgroup (43 patients) showed improved survival compared with the unvaccinated subgroup (87 patients), with a reported p-value of 0.01. Because the human analysis is retrospective and non-randomized, the findings support a plausible biological hypothesis but do not yet justify changes to clinical practice without prospective randomized trials.\",\n  \"what_is_new\": [\n    \"The work links intratumoral mRNA vaccination to an interferon-rich tumor state that can sensitize tumors to anti-PD-L1 therapy.\",\n    \"It reports broader antigen presentation after vaccination, with higher fractions of proteins represented in the immunopeptidome and the MHC-I peptidome.\",\n    \"It pairs preclinical mouse evidence with a retrospective human cohort comparison by SARS-CoV-2 mRNA vaccination status during ICI treatment.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human survival comparison is retrospective and non-randomized, so residual confounding is likely.\",\n    \"Vaccination timing relative to ICI initiation varied, and tumor types and prior treatments were heterogeneous.\",\n    \"Mouse model results may not translate directly to all human tumors, and some mechanistic signals were strongest in specific settings.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"Intratumoral\",\n      \"definition\": \"A route of administration in which a treatment is delivered directly into the tumor rather than systemically.\"\n    },\n    {\n      \"term\": \"mRNA vaccine\",\n      \"definition\": \"A vaccine platform that uses messenger RNA to instruct cells to produce a protein that can trigger immune activation.\"\n    },\n    {\n      \"term\": \"Type I interferon\",\n      \"definition\": \"A family of immune signaling molecules involved in antiviral defense that can also promote inflammation and antigen presentation.\"\n    },\n    {\n      \"term\": \"Immune checkpoint inhibitor (ICI)\",\n      \"definition\": \"A cancer therapy that blocks inhibitory immune pathways, such as PD-1/PD-L1, to help T cells attack tumors.\"\n    },\n    {\n      \"term\": \"MHC-I\",\n      \"definition\": \"A molecule on cells that presents peptide fragments to CD8+ T cells, helping the immune system recognize abnormal cells.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Would the sensitization effect hold up in prospective randomized clinical trials across different tumor types?\",\n    \"How much do vaccination timing and dose relative to ICI initiation influence outcomes and immune readouts?\",\n    \"Which patients or tumor features predict the strongest interferon induction and antigen-presentation changes after intratumoral mRNA vaccination?\"\n  ]\n}"
            },
            "output": "Successfully wrote file: output/public_summary.json",
            "callId": "call_0Iy18wGG9FN5zyLcL9Qinapo"
          }
        ],
        "usage": {
          "promptTokens": 6442,
          "cachedTokens": 0,
          "responseTokens": 3661,
          "thinkingTokens": 196,
          "totalTokens": 10299
        },
        "costUsd": 0.0652715
      },
      {
        "step": 6,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "- [x] `output/study_overview.json` written (matches `schemas/study_overview.schema.json`)\n- [x] `output/quantitative_findings.json` written (matches `schemas/quantitative_findings.schema.json`)\n- [x] `output/claim_audit.json` written (matches `schemas/claim_audit.schema.json`)\n- [x] `output/public_summary.json` written (matches `schemas/public_summary.schema.json`)",
        "toolCalls": [],
        "usage": {
          "promptTokens": 10375,
          "cachedTokens": 6272,
          "responseTokens": 100,
          "thinkingTokens": 397,
          "totalTokens": 10872
        },
        "costUsd": 0.015235849999999999
      }
    ],
    "totalCostUsd": 0.1122212
  }
}
